Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. - Wikidata - awgldk - TriplyDB

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.

http://www.wikidata.org/entity/Q43299267

about

Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Renal cell cancer: overview of the current therapeutic landscape.Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy.Molecular mechanisms of resistance to tumour anti-angiogenic strategies Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clin Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.Advances in renal cell carcinoma treatment.Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.Current status of targeted therapy for advanced renal cell carcinoma Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.Meta-analysis of dermatological toxicities associated with sorafenib.Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan.Sunitinib malate for the treatment of renal cell carcinoma.Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.Second-line systemic therapy for the treatment of metastatic renal cell cancer.Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Second-line treatment for renal cell cancer.Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines.

P2860

Q27003304-383CDD8F-F0C2-4793-8777-1AC80EE2DED3 Q30248354-4B13F2E6-4FB1-4395-B138-436612CA75C6 Q33606102-AA869C7F-8A07-48B9-B366-06F159AB7E5D Q33633424-316312F4-4F98-434A-9C6F-591A6CECAB97 Q33652827-E40B34A2-6D6C-4637-9905-BF43B2111127 Q33718025-7D62FC1F-1785-4929-8A24-0CFC967CE90C Q33737641-615FE2BC-A641-4253-A15C-73CADC323E98 Q33770680-E9D39BB3-CF7C-4F2C-B269-931539EE9B53 Q34206601-F772081D-33D3-4DE5-9A51-5D13241CAE33 Q34300621-4A4B7640-61D9-4E34-875B-B3E7401B0E1F Q34554398-3BAB15F2-197F-4E9A-A20F-215459AAEDFD Q34658095-DAC4C28D-0F07-4034-8EC4-3A918A207227 Q34779020-0EBAF2B7-84BA-4859-BD30-F9749DC7D325 Q35076407-88631E2F-6E81-4EC6-9ACE-BF87C4372311 Q35583953-15DFD1DF-6AA2-4CCB-B1E0-41D1C40845B1 Q35903850-5DC1C1F2-8955-43F2-B53C-3A6E49924639 Q35927136-ABDD812E-0253-403B-B066-0E77E847802C Q35947955-D5ADDBF4-F037-4F81-B99B-33C5A7523BA6 Q37283720-115D39BD-F381-4822-8643-C4E075D2CAF5 Q37438970-0E502EAD-2D4C-4A7B-AC0F-12206B29F631 Q37838448-ADB6D4B9-EEF9-48E1-A76E-C86B324F0223 Q37866796-932A5BBE-6053-4D7A-B9A0-7FD9CDB9D49E Q37867169-9903F28F-84C6-4F4D-9C71-A4D2DB76C7B9 Q37898560-54BE3416-130E-4C27-902A-2E4A2CF894E6 Q37997462-F5E99D54-0F70-4785-AF86-6ACB39844A41 Q38011201-2E9F09ED-585C-4952-9809-0452853F9D30 Q38016794-327C017B-F41C-4C49-95BA-E630372B6118 Q38020244-C5E93406-4D82-4EE3-B497-1B626AAE3273 Q38025626-A7A07BEE-294B-41EB-A566-0364837B4404 Q38068584-9E842B78-D1C8-4DA0-9766-1D883E088F89 Q38095926-D8A2125B-FBAB-4FCB-982A-7273299815DB Q38103397-BB2F3CC4-D085-4735-BFDE-47988165F273 Q38188423-A9CE7ABF-8165-4994-9D59-291B3E4FCCC4 Q38189898-58414401-03C3-4406-8F6E-72D5907E85AC Q39008859-40B3EDEE-B8C4-4636-BD7E-A0F95CAD8698 Q42551794-68814B77-0473-46F8-9C73-152EA6FACBB7 Q42921533-AA18AEEB-F21D-41A0-AF61-14CD196D3E2A Q44049376-7E4CE199-760D-4144-977B-DBE171CA8E26 Q45026359-7576F735-0CA3-423D-8414-FD4E9CA82E91 Q46274363-D0C07AE6-1824-44D1-9235-BA5FE3F165D8

P2860

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.

http://www.wikidata.org/entity/Q43299267

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Phase II study of sorafenib in ...... metastatic renal cell cancer.

@en

Phase II study of sorafenib in ...... metastatic renal cell cancer.

@nl

type

label

Phase II study of sorafenib in ...... metastatic renal cell cancer.

@en

Phase II study of sorafenib in ...... metastatic renal cell cancer.

@nl

prefLabel

Phase II study of sorafenib in ...... metastatic renal cell cancer.

@en

Phase II study of sorafenib in ...... metastatic renal cell cancer.

@nl

P1433

Q43299267-250230DC-7F6D-4977-BCB2-7DBF8C8ADA98

P1476

Q43299267-609484F4-1BCD-4EC0-92E8-A45594C68A3E

P2093

Q43299267-054D842C-A6C2-4EFC-9FBE-61FBD7577DA7

Q43299267-373E4C2C-DBA1-435F-92DE-11F46CB45107

Q43299267-3D4E71A0-3E5E-4DE3-AA14-6AC65CFE4F23

Q43299267-442305DD-CB37-43B4-AFCA-C1CCC98A94EB

Q43299267-54AE1442-06F5-4576-BF3B-7EAB74C88DB5

Q43299267-76E0244F-ECA6-47BC-8467-8F351F38CFCB

Q43299267-8BE1CAEB-8302-4E18-8CB4-53D0DB246493

Q43299267-92F7389F-D7F9-4E2D-BE51-9DD2F2B15E03

Q43299267-9996EC64-1A52-4E77-B141-DFC238E3F347

Q43299267-BE4FFD68-CECE-4A4B-B84A-8C9DB5481979

P304

Q43299267-125F1A67-F910-4BA3-9AE9-C0C1A8FF4F91

P31

Q43299267-A3E66028-033B-4D6B-B7DD-2771CA2BABDA

P356

Q43299267-2D19CC61-C0B3-4833-BB44-F89D59701569

P407

Q43299267-BC1ADA35-34B3-4745-91BC-0A1184DAA210

P433

Q43299267-64C3B63C-E556-4CE9-89A7-F9AA91DAB3BE

P478

Q43299267-C4F47D69-C8BA-4A08-B21E-5D366EF71D53

P50

Q43299267-B861BD13-7ABF-4E10-8BEC-D8FDF6EEE6E5

Q43299267-CE37A22F-F505-4F44-8ABB-2C57ABF4A466

P577

Q43299267-1300BB20-8340-407E-90F5-2B1BD0DE0CE7

P698

Q43299267-DE937858-72B3-4AAC-832C-4E0A4336BA82

P356

JCO.2009.22.6480

P1433

Journal of Clinical Oncology

P1476

Phase II study of sorafenib in ...... metastatic renal cell cancer.

@en

P2093

Antonio Gonnella

http://www.w3.org/2001/XMLSchema#string

Ciro Imbimbo

http://www.w3.org/2001/XMLSchema#string

Corrado Ficorella

http://www.w3.org/2001/XMLSchema#string

Gianluca Giannarini

http://www.w3.org/2001/XMLSchema#string

Gianni Bruni

http://www.w3.org/2001/XMLSchema#string

Giovannella Palmieri

http://www.w3.org/2001/XMLSchema#string

Giuseppe Di Lorenzo

http://www.w3.org/2001/XMLSchema#string

Marianna Tudini

http://www.w3.org/2001/XMLSchema#string

Michele Aieta

http://www.w3.org/2001/XMLSchema#string

Michele De Laurentiis

http://www.w3.org/2001/XMLSchema#string

P304

4469-4474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.22.6480

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Giacomo Cartenì

Riccardo Autorino

P577

2009-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19652053

http://www.w3.org/2001/XMLSchema#string